Existing dopaminergic therapies for Parkinson's disease

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 12, 2006, Pages 1613-1625

  Dutta, Aloke K ^a   Le, Weidong ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

COMT inhibitors; Dopamine agonists; MAO inhibitors; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DIHYDROERGOCRYPTINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; ENTACAPONE; ERGOT DERIVATIVE; LERGOTRILE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; NEUROPROTECTIVE AGENT; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SAFINAMIDE; SELEGILINE; TALIPEXOLE; TOLCAPONE; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEGENERATIVE DISEASE; DIARRHEA; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSKINESIA; EDITORIAL; HUMAN; MENTAL DISEASE; MONOTHERAPY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MUTATIONAL ANALYSIS; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOGENESIS; SUBSTANTIA NIGRA; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

EID: 33845897393     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.12.1613     Document Type: Editorial

References (133)

1. BRAAK HD, RUB U, DE VOS RA, JANSEN STEUR EN, BRAAK E: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. (2003) 24:197-211.
2. WOOTEN GF: Movement disorders. Neurologic principles and practice. In: Neurochemistry and neuropharmacology of Parkinson's disease. Watts RL, Koller WC (Eds). McGraw-Hill, New York, USA (1997) 153-160.
3. MOURADIAN MM: Recent advances in the genetics and pathogenesis of Parkinson's disease. Neurology. (2002) 58(2):179-185.
4. MOORE DJ, WEST AB, DAWSON VL, DAWSON TM: Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. (2005) 28:57-87.
5. PAULUS W, JELLINGER K: The neuropathologic basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. (1991) 50(6):743-755.
6. SHERER TB, XRBET R, GRFENAMYRE JT: Pathogenesis of Parkinson's disease. Curr. Opin. Investig. Drugs. (2001) 2(5):657-662.
7. FORNO LS: Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. (1996) 55(3):259-272.
8. SPILLANTINI MG, SCHMIDT ML, LEE VM, TROJANOWSKI JQ, JAKES R, GOEDERT M: α-Synuclein in Lewy bodies. Nature (1997) 388(6645):839-840.
9. JFNNER P: Oxidative stress in Parkinson's disease. Ann. Neurol. (2003) 53(Suppl. 3):S26-S36.
10. DAWSON TM, DAWSON VL: Molecular pathways of neurodegeneration in Parkinson's disease. Science. (2003) 302(5646):819-822.
11. XRBET R, SHERER TB, MACKENZIE G, GARCIA-OSUNA M, PANOV AV, GREENAMYRE JT: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. (2000) 3(12):1301-1306.
12. LANGSTON JW, BALLARD P, TETRUD JW, IRWIN I: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 219(4587):979-980.
13. SINGER TP. RAMSAY RR: Mechanism of the neurotoxicity of MPTP. An update. FEBS Lett. (1990) 274(1-2):1-8.
14. VILA M, PRZEDBORSKI S: Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. (2003) 4(5):365-375.
15. FAHN S, COHEN G: The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. (1992) 32(6):804-812.
16. JENNER P, OLANOW CW: Understanding cell death in Parkinson's disease. Ann. Neurol. (1998) 44(3 Suppl. 1):S72-S84.
17. DEXTER DT, SlAN J, ROSE S et al.: Indices of oxidative stress, mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. (1994) 35(1)38-44.
18. DEXTER DT, CARAYON A, JAVOY-AGID F et al.: Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain. (1991) 114(Pt. 4):1953-1975.
19. SAGGU H, COOKSEY J, DEXTER D et al.: A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. (1989) 53(3):692-697.
20. JENNER P: Oxidative stress as a cause of Parkinson's disease. Acta. Neurol. Scand. Suppl. (1991) 136:6-15.
21. ORELAND L: MAO, dopamine and Parkinson's disease. Acta. Neurol. Scand. Suppl. (1991) 136:60-65.
22. STOOF JC, WINOGRODZKA A, VAN MUISWINKEL FL et al.: Leads for the development of neuroprotective treatment in Parkinson's disease, brain imaging methods for estimating treatment efficacy. Eur. J. Pharmacol. (1999) 375(1-3):75-86.
23. MEISTER A, ANDERSON ME: Glutathione. Annu. Rev. Biochem. (1983) 52:711-760.
24. SIAN J, DEXTER DT, LEES AJ, DANIEL S, JENNER P, MARSDEN CD: Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. (1994) 36(3):356-361.
25. OLANOW CW, TATTON WG: Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. (1999) 22:123-144.
26. POLYMEROPOULOS MH, LAVEDAN C, LEROY E et al.: Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science (1997) 276(5321):2045-2047.
27. KRUGER R, KUHN W, MULLER T et al.: Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. (1998) 18(2):106-108.
28. CONWAY KA, ROCHET JC, BIEGANSKI RM, LANSBURY PT Jr: Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science (2001) 294(5545):1346-1349.
29. XU J, KAO SY, LEE FJ, SONG W, JIN LW, YANKNER BA: Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nat. Med. (2002) 8(6):600-606.
30. LEROY E, BOYER R, AUBURGER G et al.: The ubiquitin pathway in Parkinson's disease. Nature (1998) 395(6701):451-452.
31. KITADA T, ASAKAWA S, HATTORI N et al.: Mutations in the Parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 392(6676):605-608.
32. LE W, APPEL SH: Mutant genes responsible for Parkinson's disease. Curr. Opin. Pharmacol. (2004) 4(1):79-84.
33. SAVITT JM, DAWSON VL, DAWSON TM: Diagnosis and treatment of Parkinson's disease: molecules to medicine. J. Clin. Invest. (2006) 116(7):1744-1754.
34. TUITE P, RISS J: Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin. Investig. Drugs. (2003) 12(8):1335-1352.
35. WU SS, FRUCHT SJ: Treatment of Parkinson's disease: what's on the horizon? CNS Drugs. (2005) 19(9):723-743.
36. JOHNSTON TH, BROTCHIE JM: Drugs in development for Parkinson's disease: an update. Curr. Opin. Investig. Drugs (2006) 7(1):25-32.
37. JOHNSTON TH, BROTCHIE JM: Drugs in development for Parkinson's disease. Curr. Opin. Investig. Drugs (2004) 5(7):720-726
38. KUAN WL, BARKER RA: New therapeutic approaches to Parkinson's disease including neural transplants. Neurorehabil. Neural. Repair (2005) 19(3):155-181.
39. FOLEY P, GERLACH M, DOUBLE KL, RIEDERER P: Dopamine receptor agonists in the therapy of Parkinson's disease. J. Neural Transm. (2004) 111(10-11):1375-1446
40. SCHAPIRA AH, OLANOW CW: Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann. Neurol. (2003) 53(Suppl. 3):S149-S157.
41. CLARKE CE, GUTTMAN M: Dopamine agonist monotherapy in Parkinson's disease. Lancet (2002) 360(9347):1767-1769.
42. LLEDO A: Dopamine agonists: the treatment for Parkinson's disease in the XXI century? Parkinsonism Relat. Disord. (2001) 7:51-58.
43. BIRKMAYER W, HORNYKIEWICZ O: The effect of 1-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. Wien. Klin. Wochenschr. (2001) 113(22):851-854.
44. COTZIAS GC, PAPAVASILIOU PS, GELLENE R: Modification of Parkinsonism chronic treatment with L-dopa. N. Engl. J. Med. (1969) 280(7):337-345.
45. LOPEZ A, MUNOZ A, GUERRA MJ, LABANDEIRA-GARCIA JL: Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience. (2001) 103(3):639-651.
46. MARSDEN CD, PARKES JD: "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. (1976) 1(7954):292-296.
47. FAHN S: Is levodopa toxic? Neurology (1996) 47(6 Suppl. 3):S184-S195.
48. OLANOW CW: Oxidation reactions in Parkinson's disease. Neurology. (1990) 40(10 Suppl. 3):32-37.
49. STOCCHI F, QUINN NP, BARBATOL L et al.: Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical, pharmacokinetic study. Clin. Neuropharmacol. (1994) 17(1)38-44.
50. TOLOSA ES, VALLDEORIOLA F, MARTI MJ: New, emerging strategies for improving levodopa treatment. Neurology (1994) 44(7 Suppl. 6):S35-S44.
51. KEBABIAN JW, CALNE DB: Multiple receptors for dopamine. Nature (1979) 277(5692):93-96.
52. 3 receptor and identification of its chromosome. C. R. Acad. Sci. X. (1990) 311(13):501-508.
53. 3) as a target for neuroleptics. Nature (1990) 347(6289):146-151.
54. 4 receptor with high affinity for the antipsychotic clozapine. Nature (1991) 350(6319):610-614.
55. 1. Nature (1991) 350(6319):614-619.
56. STRANGE PG: New insights into dopamine receptors in the CNS. Neurochem. Int. (1993) 22(3):223-236.
57. CIVELLI O, BUNZOW JR, GRANDY DK: Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol. (1993) 33:281-307.
58. EMILIEN G, MALOTEAUX JM, GEURTS M, HOOGENBERG K, CRAGG S: Dopamine receptors - physiological understanding to therapeutic intervention potential. Pharmacol. Ther. (1999) 84(2):133-156.
59. OLANOW CW, JENNER P, BROOKS D: Dopamine agonists and neuroprorection in Parkinson's disease. Ann. Neurol. (1998) 44(3 Suppl. 1):S167-S174.
60. OLANOW CW, FAHN S, MUENTER M et al.: A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov. Disord. (1994) 9(1):40-47.
61. KONDO T. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. J. Neurol. (2002) 249(Suppl. 2):II25-II29.
62. 3 dopamine receptor agonists. Parkinsonism Relat. Disord. (2001) 7(3):213-223.
63. BEZARD E, BROTCHIE JM, GROSS CE: Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. (2001) 2(8):577-588.
64. 3 receptor function. Nat. Med. (2003) 9(6):762-767.
65. 3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxy phenyl)piperazinyl)buryl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J. Pharmacol. Exp. Ther. (2004) 311(2):770-777.
66. LEES AJ, STERN GM: Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (1981) 44(11):1020-1023.
67. RINNE UK, BRACCO F, CHOUZA C et al.: Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs. (1998) 55(Suppl. 1):23-30.
68. RASCOL O, BROOKS DJ, BRUNT ER, KORCZYN AD, POEWE WH, STOCCHI F: Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov. Disord. (1998) 13(1)39-45.
69. MILLAN MJ, MAIOFISS L, CUSSAC D, AUDINOT V, BOUTIN JA, NEWMAN-TANCREDI A: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native, cloned human receptor subtypes. J. Pharmacol. Exp. Ther. (2002) 303(2):791-804.
70. 2-adrenoceptor. J. Pharmacol. Exp. Ther. (2002) 303(2):805-814.
71. 3 receptors. Eur. J. Pharmacol. (1999) 366(2-3):293-300.
72. WATTS RL: The role of dopamine agonists in early Parkinson's disease. Neurology. (1997) 49(1 Suppl. 1):S34-S48.
73. ASANUMA M, OGAWA N, NISHIBAYASHI S, KAWAI M, KONDO Y. IWATA E: Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Arch. Int. Pharmacodyn. Ther. (1995) 329(2):221-230.
74. GILLE G, RAUSCH WD, HUNG ST et al.: Pergolide protects dopaminergic neurons in primary culture under stress conditions. J. Neural Transm. (2002) 109(5-6):633-643.
75. OGAWA N, TANAKA K, ASANUMA M et al.: Bromocriptine protects mice against 6-hydroxydopamine, scavenges hydroxyl free radicals in vitro. Brain Res. (1994) 657(1-2):207-213.
76. GOMEZ-VARGAS M, NISHIBAYASHI-ASANUMA S, ASANUMA M, KONDO Y, IWATA E, OGAWA N: Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res. (1998) 790(1-2):202-208.
77. 2 receptor-mediated antioxidant, neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. (1999) 838(1-2):51-59.
78. 2 agonist. Pharmacol. Biochem. Behav. (1991) 38(1):147-154.
79. BENNETT JP Jr, PIERCEY MF: Pramipexole - a new dopamine agonist for the treatment of Parkinson's disease. J. Neuro. Sciences (1999) 163(1):25-31.
80. LE WD, JANKOVIC J, XIE W, APPEL SH: Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J. Neural Transm. (2000) 107(10):1165-1173.
81. CASSARINO DS, FALL CP, SMITH TS, BENNETT JP Jr: Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methytpyridinium ion. J. Neurochem. (1998) 71(1):295-301.
82. PARKINSON STUDY GROUP: Dopamine transporter brain imaging to assess the effects of pramipexole versus levodopa on Parkinson's disease progression. JAMA. (2002) 287(13):1653-1661.
83. TAKATA K, KITAMURA Y, KAKIMURA J, KOHNO Y, TANIGUCHI T: Increase of Bcl-2 protein in neuronal dendritic processes of cerebral cortex, hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. Brain Res. (2000) 872(1-2):236-241.
84. 3 receptor as a therapeutic target for antipsychotic, antiparkinsonian drugs. Pharmacol. Therapeut. (2001) 90(2-3):231-259.
85. 3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J. Pharmacol. Exp. Ther. (1999) 289(1):202-210.
86. 3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur. J. Neurosci. (2005) 22(10):2422-2430.
87. COLLINS GG, SANDLER M, WILLIAMS ED, YOUDIM MB: Multiple forms of human brain mitochondrial MAO. Nature (1970) 225(5235):817-820.
88. SHIH JC, CHEN K, RIDD MJ: MAO: from genes to behavior. Annu. Rev. Neurosci. (1999) 22:197-217.
89. SCHACHTER M, MARSDEN CD, PARKES JD, JENNER P, TESTA B: Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J. Neurol. Neurosurg. Psychiatry (1980) 43(11):1016-1021.
90. RIEDERER P, LACHENMAYFR L, LAUX G: Clinical applications of MAO inhibitors. Curr. Med. Chem. (2004) 11(15):2033-2043.
91. HENCHCLIFFE C, SCHUMACHER HC, BURGUT FT: Recent advances in Parkinson's disease therapy: use of MAO inhibitors. Expert Rev. Neurother. (2005) 5(6):811-821.
92. MYLLYLA VV, SOTANIEMI KA, VUORINEN JA, HEINONEN EH: Selegiline in de novo parkinsonian patients: the Finnish study. Mov. Disord. (1993) 8(Suppl. 1):S41-S44.
93. HUBBLE JP, KOLLER WC, WATERS C: Effects of selegiline dosing on motor fluctuations in Parkinson's disease. Clin. Neuropharmacol. (1993) 16(1):83-87.
94. BEN-SHLOMO Y, CHURCHYARD A, HEAD J et al.: Investigation by Parkinson's Disease Research Group of UK into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ. (1998) 316(7139):1191-1196.
95. AALTONEN H, KILKKU O, HEINONEN E, MAKI-IKOLA O: Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality. BMJ. (1998) 317(7172):1586-1587.
96. OLANOW CW, MYLLYLA VV, SOTANIEMI KA et al.: Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology. (1998) 51(3):825-830.
97. WATERS CH, SETHI KD, HAUSER RA, MOLHO E, BERTONI JM: Zydis selegiline reduces off-time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord. (2004) 19(4):426-432.
98. STERLING J, VEINBERG A, LERNER D et al.: (R)(+)-N-propargyl-l-aminoindan (rasagiline), derivatives: highly selective and potent inhibitors of MAOB. J. Neural Transm. Suppl. (1998) 52:301-305.
99. YOUDIM MB, GROSS A, FINBERG JP: Rasagiline [N-propargyl-1R(+)-amino indan], a selective, potent inhibitor of mitochondrial MAO-B. Br. J. Pharmacol. (2001) 132(2):500-506.
100. TABAKMAN R, LECHT S, LAZAROVICI P: Neuroprotection by MAOB inhibitors: a therapeutic strategy for Parkinson's disease? BioEssays. (2004) 26(1):80-90.
101. YOUDIM MB, WEINSTOCK M: Molecular basis of neuroprotective activities of rasagiline, the anti-Alzheimer drug TV3326 ([N-propargyl-[3R]aminoindan-5-YL]-ethyl methyl carbamate). Cell. Mol. Neurobiol. (2001) 21(6):555-573.
102. BLANDINI F, ARMENTERO MT, FANCELLU R, BLAUGRUND E, NAPPI G: Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp. Neurol. (2004) 187(2):455-459.
103. MARUYAMA W, YAMAMOTO T, KITANI K, CARRILLO MC, YOUDIM M, NAOI M: Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech. Ageing Dev. (2000) 116(2-3):181-191.
104. STOCCHI F, ARNOLD G, ONOFRJ M et al.: Improvement of motor function in early Parkinson disease by safinamide. Neurology (2004) 63(4):746-748.
105. YI H, MARUYAMA W, AKAO Y et al.: N-propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural Transm. (2006) 113(1):21-32.
106. AXELROD J, SENOH S, WITKOP B: O-methylation of catechol amines in vivo. J. Biol. Chem. (1958) 233(3):697-701.
107. MANNISTO PT, ULMANEN I, LUNDSTROM K et al.: Characteristics of catechol-O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog. Drug Res. (1992) 39:291-350.
108. MANNISTO PT, KAAKKOLA S: Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol. Toxicol. (1990) 66(5):317-323.
109. MULLER T, ERDMANN C, MUHLACK S, BREMEN D, PRZUNTEK H, WOITALLA D: Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov. Disord. (2006) 21(3):332-336.
110. WIDNELL KL, COMELLA C: Role of COMT inhibitors, dopamine agonists in the treatment of motor fluctuations. Mov. Disord. (2005) 20(Suppl. 11):S30-S37.
111. BORRONI E, BORGULYA J, ZURCHER G: Mose Da Prada, the discovery of tolcapone. J. Neural Transm. Suppl. (1998) 52:XIII-XVI.
112. NISSINEN E, LINDEN IB, SCHULTZ E, POHTO P: Biochemical, pharmacological properties of a peripherally acting carechol-O-merhyltransferase inhibitor entacapone. Naunyn. Schmiedebergs Arch. Pharmacol. (1992) 346(3):262-266.
113. ROBERTS JW, CORA-LOCATELLI G, BRAVI D, AMANTEA MA, MOURADIAN MM, CHASE TN: Catechol-O-methyltransferase inhibitor tolcapone, prolongs levodopa/ carbidopa action in Parkinsonian patients. Neurology. (1993) 43(12):2685-2688.
114. KURTH MC, ADLER CH, HILAIRE MS et al.: Totcapone improves motor function, reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology. (1997) 48(1):81-87.
115. NAJIB J: Entacapone: a catechot-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin. Ther. (2001) 23(6):802-832; discussion 771.
116. ONOFRJ M, THOMAS A, IACONO D, DI IORIO A, BONANNI L: Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur. Neurol. (2001) 46(1):11-16.
117. MULLER T, KUHN W. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine, homocysteine in treated Parkinson's disease patients. Eur. J. Clin. Pharmacol. (2006) 62(6):447-450.
118. LAMBERTI F, ZOCCOLELLA S, ILICETO G et al.: Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov. Disord. (2005) 20(1):69-72.
119. POSTUMA RB, LANG AE: Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology (2004) 63(5):886-891.
120. JANKOVIC J: Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. (2005) 20(Suppl. 11):S11-S16.
121. STOCCHI F: Oprimising levodopa therapy for the management of Parkinson's disease. J. Neurology. (2005) 252(Suppl. 4):IV43-IV48.
122. HEIKKINEN H, NUTT JG, LEWITT PA, KOLLER WC, GORDIN A: The effects of different repeated doses of entacapone on the pharmacokinetics of L-dopa and on the clinical response to L-dopa in Parkinson's disease. Clin. Neuropharmacol. (2001) 24(3):150-157.
123. BROOKS DJ, AGID Y, EGGERT K, WIDNER H, OSTERGAARD K, HOLOPAINEN A: Treatment of end-of-dose wearing-off in Parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur. Neurol. (2005) 53(4):197-202.
124. GULDENPFENNIG WM, POOLE KH, SOMMERVILLE KW, BOROOJERDI B: Safety, tolerability and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson's disease. Clin. Neuropharmacol, (2005) 28(3):106-110.
125. WHONE AL, WATTS RL, STOESSL AJ et al.: Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. (2003) 54(1):93-101.
126. CHEN JJ, SWOPE DM: Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J. Clin. Pharmacol (2005) 45(8):878-894.
127. 2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs (2005) 14(6):729-738.
128. 1A agonist in advanced Parkinson's disease. Mov. Disord. (2005) 20(8):932-936.
129. +-induced dopamine neuron injury. Life Sci. (2003) 72(9):1073-1083.
130. BONIFATI V, RIZZU P, VAN BAREN MJ et al.: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (2003) 299(5604):256-259.
131. PAISAN-RUIZ C, JAIN S, EVANS EW et al.: Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 44(4):595-600.
132. VALENTE EM, ABOU-SLEIMAN PM, CAPUTO V et al.: Hereditary early-onset Parkinson's disease caused by mutations in PINK-1. Science (2004) 304(5674):1158-1160.
133. SINGLETON AB, FARRER M, JOHNSON et al.: α-Synuclein locus triplication causes Parkinson's disease. Science (2003) 302(5646):841.